Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

Benzinga Newsdesk www.benzinga.com Positive 85.0%

Neg 0% Neu 0% Pos 85%

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.